TP53 Germline Mutations: Beyond LFS
TP53 种系突变:超越 LFS
基本信息
- 批准号:10397062
- 负责人:
- 金额:$ 35.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-10-15 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAdrenocortical carcinomaAgeAllelesAmericanAnimal ExperimentsApoptosisBasal cell carcinomaBiologicalBrain NeoplasmsBreastBreast Cancer Risk FactorBreast Epithelial CellsCancer-Predisposing GeneCarcinogen exposureCell LineCodeColonic NeoplasmsColorectal AdenomaDataDevelopmentDiseaseERBB2 geneEmbryoEsophageal Squamous Cell CarcinomaFamilyFemaleFibroblastsFoundationsFrequenciesGene FrequencyGeneral PopulationGenesGerm-Line MutationGliomaGliomagenesisHereditary DiseaseHeterozygoteHomozygoteHumanInbred BALB C MiceIncidenceIndividualInheritedLi-Fraumeni SyndromeMalignant NeoplasmsMalignant neoplasm of brainMalignant neoplasm of prostateMammary NeoplasmsMammary TumorigenesisMeasurableMessenger RNAMinorMolecularMusMutateMutationNF1 geneNeuroblastomaNucleotidesOdds RatioOncogenicOrthologous GenePathologicPatientsPenetrancePersonsPlatelet-Derived Growth FactorPolyadenylationPopulationPositioning AttributePredispositionPrevention strategyPropertyReportingRiskRoleSignal TransductionSingle Nucleotide PolymorphismSkinSoft tissue sarcomaSomatic MutationSusceptibility GeneTP53 geneTissuesTransgenic MiceTumor Suppressor ProteinsTumorigenicityUntranslated RNAVariantWild Type MouseWorkcancer cellcancer therapycancer typecell transformationhigh risklifetime riskmalemalignant breast neoplasmmammarymouse modelmutantnerve stem cellnovelosteosarcomaprostate carcinogenesisself-renewalstem cell self renewalstem cellstreatment strategytumortumorigenesisvirtual
项目摘要
Project Summary
This proposal addresses Provocative Question 1 “What molecular mechanisms influence disease penetrance
in individuals who inherit a cancer susceptibility gene?” Li-Fraumeni Syndrome (LFS) is a rare, inherited
disorder that leads to a higher risk of breast cancer, soft tissue sarcoma, osteosarcoma, brain tumor (including
glioma), adrenal cortical carcinoma, and other cancers. TP53, encoding the p53 tumor suppressor, is mutated
in ~75% of LFS families. TP53 mutations in LFS patients occur in the coding sequence (CDS) and produce
mutant p53 proteins that lack most or all normal tumor-suppressive functions and often confer oncogenic
properties. Beyond LFS mutants, over 200 naturally occurring germline mutants of TP53 are known, yet only a
few of them cause measurable perturbation of p53 function. Recent reports demonstrate that a single
nucleotide polymorphism in a TP53 noncoding region predisposes carriers to multiple types of cancer including
glioma, neuroblastoma, skin basal cell carcinoma, esophageal squamous cell carcinoma, prostate cancer, and
colorectal adenoma. As such, cancer susceptibility of this p53 noncoding mutant does not strictly mirror that of
p53 germline mutations in LFS patients. Specifically, this noncoding mutant confers no increased risk of
breast cancer, the most common LFS tumor, whereas it shares similarity with LFS mutants in glioma
predisposition. This p53 mutant is positioned uniquely among known cancer-susceptibility alleles in that it is
noncoding and present at higher frequency (~1 in 50 in general populations, i.e., over 6 million Americans and
100 million people worldwide carry this mutant). We hypothesize that the moderate reduction of p53
activity by the noncoding mutant predisposes carriers to glioma but not breast cancer. In this study, we
will employ mouse models and cell lines to ascertain the causative role of this p53 noncoding mutant in cancer
by comparing it with an LFS coding sequence mutant. In Aim 1, we will determine whether the p53 mutant
increases glioma development in mice. In Aim 2, we will determine the role of this mutant in mammary tumor
development in mice and in human breast epithelial cell transformation. In Aim 3, we will dissect the
mechanisms of the p53 PAS mutant in tumorigenesis in comparison with an LFS mutant using mammary stem
cells and neural stem cells. Data generated from this study will reveal the biological and pathologic function of
p53 germline mutants beyond its established role in LFS. This project has potentially broad and far-reaching
significance in that our findings will reveal mechanistic causal connections between germline variation and
tissue-specific cancer penetrance.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yong Li其他文献
A chimeric vacuolar Na+/H+ antiporter gene evolved by DNA family shuf?ing confers increased salt tolerance in yeast
由 DNA 家族改组进化而来的嵌合液泡 Na /H 逆向转运蛋白基因可增强酵母的耐盐性
- DOI:
- 发表时间:
2015 - 期刊:
- 影响因子:0
- 作者:
Yong Li;Hailing Gao;Jiang Wu;Wenzhu Guan - 通讯作者:
Wenzhu Guan
Yong Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yong Li', 18)}}的其他基金
Optimizing Syngeneic Mouse Models to Target Mutant p53
优化同基因小鼠模型以靶向突变 p53
- 批准号:
10677353 - 财政年份:2023
- 资助金额:
$ 35.87万 - 项目类别:
Cancer Prevention-Interception Against MGUS Progression
癌症预防——阻止 MGUS 进展
- 批准号:
10745010 - 财政年份:2023
- 资助金额:
$ 35.87万 - 项目类别:
Therapeutic Targeting a Non-Hodgkin Lymphoma Driver Using AI
使用人工智能针对非霍奇金淋巴瘤驱动者进行治疗
- 批准号:
10585717 - 财政年份:2022
- 资助金额:
$ 35.87万 - 项目类别:
Modulation of MicroRNAs with Xenobiotics to Target c-Myc
用异生素调节 MicroRNA 以靶向 c-Myc
- 批准号:
10018536 - 财政年份:2019
- 资助金额:
$ 35.87万 - 项目类别:
MYC as a Biomarker in Aggressive Non-Hodgkin Lymphoma
MYC 作为侵袭性非霍奇金淋巴瘤的生物标志物
- 批准号:
10019120 - 财政年份:2019
- 资助金额:
$ 35.87万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 35.87万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 35.87万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 35.87万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 35.87万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 35.87万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 35.87万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 35.87万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 35.87万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 35.87万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 35.87万 - 项目类别:
Research Grant